Meeting Coverage

ASH: Hematology

American Society of Hematology

Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's

3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab

ASH over a photo of Ernest N. Morial Convention Center in New Orleans, Louisiana.

Latest ASH: Hematology Meeting Coverage

New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT

Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk

December 14, 2022
'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL

Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease

December 14, 2022
C3 Pathway Inhibitor May Change Practice for Paroxysmal Nocturnal Hemoglobinuria

Iptacopan improved hemoglobin without transfusion versus current standard of care

December 14, 2022
High-Dose Chemo, ASCT Improves Survival in Primary CNS Lymphoma

European trial is "practice-changing as of today," says U.S. expert

December 13, 2022
Prolonged Responses in DLBCL Spark Talk of a Cure With Bispecific Antibody

Most complete responses lasted 24 months or longer after limited-duration glofitamab

December 13, 2022
Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL

Phase III study showed 58% reduction in the risk of death versus chemo alone

December 13, 2022
Pediatric Hodgkin Lymphoma Survivors Experience Accelerated Epigenetic Aging

Data from St. Jude cohort show higher rates of neurocognitive impairment

December 13, 2022
Heparin Fails to Stop Miscarriages in Women With Inherited Thrombophilia

No difference in live birth rates with or without blood thinner

December 13, 2022
Durable Platelet Response in Immune Thrombocytopenia With Efgartigimod

Glycoprotein receptor inhibitor produces four times as many responses as placebo

December 12, 2022
Black Patients Less Likely to Get Advanced Treatments for PE

Also less likely for patients on Medicare and Medicaid

December 12, 2022
AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT

Similar outcomes if patients went directly to transplant or received intensive salvage first

December 11, 2022
Talquetamab Offers New Hope in Relapsed/Refractory Multiple Myeloma

Bispecific antibody achieves "incredible" response rates over 70% in heavily pretreated patients

December 11, 2022
Ibrutinib Makes Its Case for First-Line Treatment in Mantle Cell Lymphoma

Standard-of-care autologous transplant fails to prove superior to BTK inhibitor alone

December 11, 2022
Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT

"We should eliminate these silly neutropenic diets," expert says

December 10, 2022